A Study of A High Concentration Liquid Formulation Versus A Lyophilized Formulation of Gantenerumab in Healthy Volunteers
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This multi-center, randomized, open-label, single-dose, parallel group study will assess the
relative bioavailability, tolerability and dose-exposure relationship of a high concentration
liquid formulation (HCLF) versus a lyophilized formulation (LyoF) of gantenerumab (RO4909832)
in healthy volunteers. Subjects will be randomized to receive single subcutaneous doses of
either HCLF or LyoF. Anticipated time for treatment period and follow-up will be 13 weeks.